Oxford Haemophilia & Thrombosis Centre, Oxford University Hospitals NHS Foundation Trust, and Oxford University, NIHR BRC Haematology Theme, Oxford, UK.
Transfus Med Rev. 2021 Oct;35(4):104-107. doi: 10.1016/j.tmrv.2021.06.005. Epub 2021 Aug 25.
Fibrinogen is a key coagulation protein that is necessary for the formation of stable clots. Fibrinogen levels have been reported to be one of the first to fall during major haemorrhage reflecting consumption, dilution and fibrinogenolysis. Its role in acquired major haemorrhage, both in relation to the contribution it plays to the coagulopathy of major bleeding that can exacerbate bleeding and how effective fibrinogen supplementation can be at improving clinical outcomes, has received a great deal of attention over the last 10 - 15 years. This commentary focuses on just three of the more recent publications from the last 5 years that provide some of the evidence behind how we can think about fibrinogen as a haemostatic treatment for acquired major haemorrhage and how we can use the laboratory thresholds to guide therapy.
纤维蛋白原是一种关键的凝血蛋白，对于形成稳定的血栓是必需的。纤维蛋白原水平被报道是在大出血期间最早下降的指标之一，反映了消耗、稀释和纤维蛋白溶解。在获得性大出血中，纤维蛋白原的作用与其在可加重出血的大出血凝血障碍中的作用有关，以及纤维蛋白原补充剂在改善临床结局方面的有效性，在过去的 10-15 年中受到了极大的关注。本评论集中讨论了过去 5 年中最近的三篇出版物，这些出版物提供了一些关于如何将纤维蛋白原视为获得性大出血止血治疗的证据，以及如何使用实验室阈值来指导治疗。
